Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23079844 | 0.99 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079667 | 0.95 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079900 | 0.94 | NPC1 (0.42) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079668 | 0.94 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079907 | 0.92 | NPC1 (0.42) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079909 | 0.92 | NPC1 (0.40) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079961 | 0.92 | NPC1 (0.43) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079784 | 0.91 | NPC1 (0.41) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079839 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 | |
| SCHEMBL23079877 | 0.91 | HSD17B10 (0.49) | SMN1; SMN2KDM4EHSD17B10TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070717-A1 | ORGANIC COMPOUND BASED ON TRIAZINE AND BENZOXAZOLE AND APPLICATION THEREOF IN ORGANIC ELECTROLUMINESCENT DEVICE | JIANGSU SUNERA TECHNOLOGY CO., LTD. (CN) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070717-A1 | ORGANIC COMPOUND BASED ON TRIAZINE AND BENZOXAZOLE AND APPLICATION THEREOF IN ORGANIC ELECTROLUMINESCENT DEVICE | OCIAD1, EED, OCIAD2 | SMN1; SMN2 4531/4885KDM4E 1651/4885HSD17B10 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.